+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (DBM Putty, Others), By Application (Orthopedics, Dental), and Regional Forecast, 2026-2034
The global injectable bone putty market was valued at USD 187 million in 2025 and is estimated at USD 199 million in 2026. The market is projected to reach USD 291 million by 2034, representing a 4.9% CAGR during 2026–2034.
Injectable bone putty is used to fill selected bony voids or gaps in orthopedic and dental procedures where a moldable or injectable graft material can simplify defect filling. Products include demineralized bone matrix (DBM) formulations and synthetic calcium-based materials, with commercial differentiation based on handling, composition, resorption profile, sterility, delivery system and labeled indications.
The addressable market is supported by a large orthopedic procedural ecosystem, but procedure counts should not be interpreted as direct putty use. The AAOS American Joint Replacement Registry 2025 report analyzes more than 4.4 million procedures collected from 2012 through 2024, while the American Spine Registry highlights more than 466,000 procedures across lumbar and cervical modules. These datasets demonstrate the scale of U.S. musculoskeletal care in which bone-graft materials may be used selectively.
Recent FDA clearance activity confirms continued product development. NanoBone SBX Putty and NanoBone QD received a substantially equivalent decision in April 2025, and the Allomatrix family including Allomatrix Injectable Putty received a 510(k) decision in September 2025. These events support ongoing competition around handling, material composition and procedure-specific utility.
The study covers injectable bone putty by type, application and geography, with analysis of biomaterial performance, procedure demand, regulatory clearance, clinical workflow and competitive strategy.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | DBM Putty; Others |
| By Application | Orthopedics; Dental |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Mexico; Germany; France; United Kingdom; Italy; China; Japan; South Korea; India; Brazil and other major markets |
| Key Market Players | Medtronic; Bioteck; Zimmer Biomet; Xtant Medical; Stryker (Wright Medical); SeaSpine; BONESUPPORT |
The market includes injectable or syringe-deliverable bone-putty products used as bone void fillers or graft materials in orthopedic and dental procedures. The scope includes DBM putties and other covered synthetic or composite putty formulations.
The market excludes rigid implants, fixation hardware, bone cement used primarily for mechanical fixation, standalone granules not sold as injectable putty, and biologic products outside the report’s bone-putty definition. Revenue is assigned to the covered putty product rather than to the complete surgical episode.
AAOS registry data show a substantial U.S. procedural base across joint replacement and spine surgery. Injectable putty is not required in every procedure, but the scale of musculoskeletal surgery supports recurring demand for defect-filling and graft-extender materials in selected indications.
Putty and syringe-delivered formulations can conform to small or complex bony voids more readily than rigid blocks. Ease of placement can reduce intraoperative handling steps and support minimally invasive workflows where the labeled indication and material properties are appropriate.
Demineralized bone matrix formulations aim to provide a biologic scaffold while the carrier determines viscosity, cohesiveness and delivery. Commercial differentiation depends on DBM processing, consistency, handling and the final product’s labeled indications rather than on DBM content alone.
Calcium-based and other synthetic bone-void fillers avoid donor-tissue variability and can offer controlled resorption and handling properties. They compete with DBM putties where surgeons value predictable material composition and ready availability.
FDA clearances specify indications, anatomic use and whether a material is intended for voids not intrinsic to structural stability. Products that appear similar in handling cannot be assumed interchangeable across spine, extremity, pelvis or dental applications without appropriate labeling and evidence.
Reducing mixing steps and simplifying delivery can make a product more attractive in time-sensitive procedures. Packaging and syringe design become part of the value proposition alongside graft composition.
Manufacturers combine DBM, calcium salts, ceramics or carrier materials to tune cohesiveness, resorption and osteoconductive performance. The strongest products align these material properties with clear procedure-specific evidence.
The 2025 clearances for NanoBone SBX Putty/NanoBone QD and Allomatrix formulations show continuing product activity in U.S. bone-void fillers. New entries raise competitive pressure on handling claims, indication breadth and distributor access.
Bone-graft selection is influenced by material familiarity, preparation time, delivery method, defect geometry and institutional availability. Products that integrate smoothly into established technique can retain share even when alternative biomaterials have similar broad indications.
Hospitals and surgeons increasingly look beyond basic clearance toward clinical performance, fusion or healing evidence, complication profiles and economic value. Stronger evidence can support premium pricing and formulary retention.
Injectable bone putties differ in source material, carrier chemistry, resorption behavior, delivery and biologic function. The product selected for a procedure must match the defect, mechanical environment and labeled indication.
| Material / Design | Commercial Strength | Key Consideration |
|---|---|---|
| DBM putty | Biologic allograft-derived matrix combined with moldable or injectable handling. | Donor-tissue processing, consistency, carrier properties and labeled use. |
| Calcium-based synthetic putty | Controlled composition, broad supply availability and osteoconductive scaffold behavior. | Resorption, handling, radiographic behavior and defect environment. |
| Composite formulations | Can combine handling, structural persistence and biologic components. | More complex formulation and evidence requirements. |
| Prefilled injectable systems | Procedure convenience and controlled delivery. | Syringe force, extrusion consistency, sterility and shelf stability. |
The report divides the market into DBM putty and other injectable putty formulations. DBM is a core commercial category because it combines an allograft-derived matrix with moldable handling, while other products compete through synthetic or composite material properties.
DBM putties use demineralized allograft bone matrix with a carrier to create a moldable or injectable material. Product differentiation depends on tissue processing, DBM composition, handling, consistency and the labeled clinical indication.
Other products include calcium-based and composite bone-void fillers designed for controlled handling, resorption and osteoconduction. These products can reduce donor-tissue dependence and offer more standardized material composition.
DBM putty should remain an important category through 2034, while synthetic and composite alternatives can gain share where consistent supply, predictable handling and procedure-specific performance support adoption.
The application mix is divided between orthopedics and dental procedures. Orthopedics represents the primary application because bone-void management spans trauma, reconstruction and selected spine or extremity procedures, while dental use is concentrated in oral and maxillofacial bone regeneration.
Orthopedic demand includes selected surgically created or traumatic bone voids, graft-extender use and other labeled applications across the skeletal system. Adoption depends strongly on surgeon technique, hospital formulary and product indication.
Dental and oral-surgery applications include selected bone-grafting procedures where a putty or paste can be placed into defined defects. Products must carry appropriate dental labeling and compete with granules, membranes and other graft materials.
Orthopedics is expected to remain the larger application through 2034 because of the breadth of musculoskeletal procedures, while dental demand provides a distinct specialty opportunity for formulations with suitable handling and regulatory coverage.
Regional analysis emphasizes market structure and verifiable country-level signals that explain demand, access, regulation or product adoption. Statistics are included only where a reliable public source supports the stated year and geography.
North America leads the market through substantial orthopedic procedure volumes, broad adoption of bone-graft substitutes, strong surgeon access to commercial biomaterials and an active U.S. regulatory pathway for new bone-void fillers.
The AAOS American Joint Replacement Registry 2025 Annual Report analyzes more than 4.4 million hip and knee arthroplasty procedures collected from 2012 through 2024. The figure is a measure of orthopedic procedure scale, not direct injectable-putty utilization.
Source: AAOS / AJRR.
FDA issued 510(k) K250521 for NanoBone SBX Putty and NanoBone QD on April 7, 2025, classifying the products as resorbable calcium salt bone void fillers.
Source: U.S. FDA.
Europe has mature orthopedic, spine and dental markets with established use of synthetic and allograft-derived graft materials. Product access depends on medical-device regulatory compliance, distributor networks and country-level procurement.
Asia-Pacific demand is supported by expansion of orthopedic and dental surgical capacity in China, Japan, South Korea, India and Australia. Adoption varies by local reimbursement, surgeon familiarity, imported-device pricing and domestic biomaterials competition.
Latin American demand is concentrated in higher-complexity hospitals and specialty dental/orthopedic centers. Imported biomaterial pricing, distributor coverage and reimbursement availability influence product penetration.
Gulf healthcare systems provide opportunities for premium orthopedic biomaterials, while broader regional adoption is limited by procedure volumes, procurement budgets and specialist availability. Distributor capability is a major route-to-market factor.
Many calcium-compound bone void fillers are regulated under 21 CFR 888.3045 as Class II devices and reach the market through 510(k) substantial-equivalence review. This creates a defined path for iterative formulation and delivery-system innovation.
Demineralized bone matrix putties may have product codes and indications reflecting orthopedic or dental use. Manufacturers must match labeling, processing and evidence to the intended procedure rather than assuming one clearance supports every application.
NanoBone SBX Putty and NanoBone QD received a 2025 U.S. clearance as calcium salt bone void fillers, while the Allomatrix family including Injectable Putty received a 2025 clearance involving DBM, cancellous bone matrix and carrier components.
Allograft-derived products require controlled tissue sourcing and processing, while synthetic products require consistent raw materials, sterility and performance specifications. Hospitals evaluate these controls alongside handling and clinical evidence.
The market includes large orthopedic companies and specialist biomaterials suppliers. Competition is based on product handling, material technology, indication breadth, clinical evidence, surgeon familiarity, distribution and the ability to integrate bone-graft products into broader procedural portfolios.
Large orthopedic companies can bundle graft materials with implants, instruments and procedure support, strengthening access to hospitals and surgeon networks.
Smaller participants can differentiate with proprietary DBM processing, synthetic compositions, delivery systems and resorption profiles. Focused evidence can offset disadvantages in distribution scale.
Surgeon preference is influenced by hands-on familiarity with viscosity, extrusion and defect handling. Distributor coverage, product availability and clinical education can therefore materially affect adoption.
As comparable products enter the market, basic moldability becomes less differentiating. Prefilled delivery, predictable extrusion, shelf stability, preparation time and evidence increasingly shape premium positioning.
The syndicated report profiles the following companies within its defined competitive scope:
FDA 510(k) K252797 received a substantially equivalent decision in May 2026, illustrating continuing innovation and competitive entry in resorbable calcium-compound bone void fillers adjacent to injectable putty products.
Source: U.S. FDA.
FDA 510(k) K252085 covered Allomatrix Injectable Putty and related formulations. The submission describes DBM, cancellous bone matrix granules and a surgical-grade calcium-sulfate/carboxymethylcellulose binder.
Source: U.S. FDA.
FDA 510(k) K250521 classified the devices as resorbable calcium salt bone void fillers under 21 CFR 888.3045, adding new synthetic putty options to the U.S. market.
Source: U.S. FDA.
The market is projected to increase from USD 199 million in 2026 to USD 291 million by 2034, representing a 4.9% CAGR. Growth will be supported by procedure demand, new product clearances and continued preference for easy-to-place biomaterials in selected orthopedic and dental defects.
The breadth of musculoskeletal procedures gives orthopedics the largest addressable use base, while actual putty selection will remain highly dependent on defect type, indication and surgeon preference.
Products that deliver controlled extrusion, defect conformity and minimal preparation can improve operating-room workflow and defend value against granules or manually mixed graft materials.
DBM offers an allograft-derived matrix, while synthetic products provide controlled composition and supply consistency. Neither approach is universally superior; adoption depends on indication, evidence, handling and institutional preference.
As product choice widens, hospitals and surgeons will place greater emphasis on labeled indications, clinical data, complication experience, sterility, supply reliability and economic value.
The report covers global injectable bone putty revenue, historical and forecast trends, type and application segmentation, regional and country analysis, competitive positioning and key company profiles.
Analytical coverage includes DBM and synthetic materials, injectable delivery, orthopedic and dental workflows, product clearances, surgical demand, hospital purchasing, quality systems and competitive strategy.
Detailed company revenue, product-level pricing, procedure-specific consumption and country forecasts remain within the syndicated report deliverables and are not reproduced in the public overview.
The study combines publisher market inputs with authoritative device-regulatory records, professional registry data, peer-reviewed biomaterials literature and company primary information. External evidence is used to explain procedure demand, material technology and regulatory change.
Revenue is measured for injectable bone-putty products within the defined type and application scope, with 2025 as the base year, 2026 as the estimated year and forecasts through 2034.
Recent U.S. product developments are checked against FDA 510(k) records, including device classification, decision dates and intended product families.
Professional registry statistics are used only as indicators of orthopedic procedure scale and are not converted into injectable-putty utilization without direct evidence.
Company analysis considers biomaterial platforms, indications, handling, clinical evidence, distribution and procedure relationships without treating total corporate orthopedic revenue as injectable-putty revenue.
The market was valued at USD 187 million in 2025, is estimated at USD 199 million in 2026, and is projected to reach USD 291 million by 2034, representing a 4.9% CAGR during 2026–2034.
The report segments the market into DBM putty and other formulations, including synthetic and composite bone-void filler products within the defined scope.
Orthopedics is the primary application, while dental procedures form a smaller specialized segment with different regulatory and handling requirements.
North America is the largest region in 2025, supported by high orthopedic procedure volumes, established biomaterial use, specialist infrastructure and active U.S. product clearance.
Injectable or moldable formulations can conform to irregular bony voids, simplify placement and reduce preparation steps where the material is appropriate for the labeled indication.
DBM putty combines demineralized bone matrix with a carrier to create a moldable or injectable graft material. Product performance depends on tissue processing, carrier properties, handling and labeled use.
The report profiles Medtronic, Bioteck, Zimmer Biomet, Xtant Medical, Stryker/Wright Medical, SeaSpine and BONESUPPORT.
Recent U.S. activity includes 2025 FDA 510(k) clearances for NanoBone SBX Putty/NanoBone QD and the Allomatrix family including Injectable Putty, followed by additional bone-void filler activity in 2026.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
